IOVA Share Price Performance
US$4.31
2.56 (146.29%)
69.2% undervalued intrinsic discount
US$14.00
Fair Value
Price US$4.31
AnalystHighTarget US$14.00
AnalystLowTarget US$4.00
Polip US$18.00
Fair ValueUS$14.00
Share Pricen/a
Narrative Update • Jun 17
Iovance Biotherapeutics, Inc. Stock Price
- 4 Narratives written by author
- 4 Comments on narratives written by author
- 153 Fair Values set on narratives written by author
IOVA Community Narratives
AN
Fair Value
·Fair Value US$14 69.2% undervalued intrinsic discount
Amtagvi And New TIL Will Meet Aging Global Demand
2users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value
·Fair Value US$4 7.8% overvalued intrinsic discount
Rising Interest Rates And Dilution Will Stifle TIL Progress
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
PO
Fair Value
·Fair Value US$18 76.1% undervalued intrinsic discount
Why I think Iovance is undervalued
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Why I think Iovance is undervalued
In my opinion, Iovance is one of those biotech companies where the market is still focused on what went wrong in the past instead of what could happen over the next few years. After a disappointing commercial launch in 2025, many investors lost confidence and the share price fell sharply.Read more
Amtagvi And New TIL Will Meet Aging Global Demand
A cancer therapy company could see a quicker ramp than many expect if doctors keep adopting its newest treatment and more hospitals can offer it. But the story hinges on scaling complex manufacturing and avoiding setbacks from regulators, insurers, and fast-moving rivals.Read more
AN
US$14
69.2% undervalued intrinsic discount
Fair Value
Profit Margin
5.63%
Future PE
137.51x
Price in 2029
US$17.2
Rising Interest Rates And Dilution Will Stifle TIL Progress
Key Takeaways Sustained high costs, complex distribution, and slow commercialization delay profitability and threaten market share amid rising competition from newer cancer therapies. Ongoing financial challenges, including exposure to interest rates and revenue pressure from drug pricing scrutiny, heighten risk of shareholder dilution and reduced margins.Read more
AN
US$4
7.8% overvalued intrinsic discount
Fair Value
Profit Margin
12.78%
Future PE
32.48x
Price in 2029
US$4.92
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Key Takeaways Expanded distribution and positive clinical data are set to boost adoption of Amtagvi and strengthen revenue growth in oncology markets. Operational streamlining, new pipeline advancements, and global expansion efforts are expected to improve profitability and diversify long-term earnings.Read more
AN
US$8.35
48.4% undervalued intrinsic discount
Fair Value
Profit Margin
3.6%
Future PE
183.52x
Price in 2029
US$10.27
Trending Discussion
Recently Updated Narratives
PO
Why I think Iovance is undervalued
Fair Value: US$18 76.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IOVA: Replimune Setback And IL 12 TIL Trial Will Support Higher P/E
Fair Value: US$14 69.2% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Fair Value: US$4 7.8% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Iovance Biotherapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.79
- 39.44%
- -123.90%
- 0.1%
About IOVA
- Founded
- 2007
- Employees
- 975
- CEO
- WebsiteView website
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Recent IOVA News & Updates
Seeking Alpha • Jun 17
